Media.Player

Carcinoma Immunotoxin Targeting Epidermal Growth Factor and Interleukin-4 Receptors

技術優勢

BENEFITS OF TARGETING DRUG RESISTANT CARCINOMA CELLS WITH IMMUNOTOXINSΓÇó Immunotoxins have the ability to kill drug resistant carcinomas by an alternative mechanismΓÇó Immunotoxins take advantage of cytokine receptors present on the carcinoma cell surfaceΓÇó Higher specificity of immunotoxins can be achieved by targeting multiple receptorsΓÇó Immunotoxins can target gioblastoma cells which respond differently to conventional chemotherapy techniques

詳細技術說明

IMMUNOTOXIN FOR TARGETING REFRACTORY CARCINOMA AND GLIOBLASTOMATREATING DRUG RESISTANT CARCINOMAS WITH IMMUNOTOXINSThousands of cancer patients each year develop drug refractory cancer. Refactory cancer cells are malignant cancer cells that are resistant to chemotherapy treatments. Sometimes therapies include immunotoxins which kill carcinoma cells by a mechanism entirely unrelated to conventional chemotherapeutic agents and kill drug resistant cells. These immunotoxins are important as alternative or supplemental therapies to conventional chemotherapy treatments. One of the major challenges with immunotoxins is targeting the right carcinoma cells. Immunotoxins can be tuned to recognize different cytokine receptors on cancer cell surfaces. Cytokines are small proteins released by the immune system that are very important in cell signaling. Different types of carcinomas present different cytokine receptors on their cell surface and targeting the right ones can direct an immuntoxin towards breast, colon, lung, prostate, and brain cancer tumors.IMMUNOTOXIN FOR TARGETING SPECIFIC CARCINOMAS WITH EPIDERMAL GROWTH FACTOR AND INTERLEUKIN-4 RECEPTORSTwo major cytokine receptors present in several types of carcinomas are Epidermal Growth Factor (EGF) and Interleukin-4 (IL-4). An immunotoxin, EGF4KDEL, with both EGF and Interleukin-4 present on the same truncated diphtheria toxin chain has sufficiently greater carcinoma killing activity than immunotoxins that target either EGF or IL-4 separately. This has been shown to be effective on prostate, colon, lung, pancreatic, and breast cancer cells. Aside from this broad spectrum of carcinomas, EGF4KDEL has also shown an enhanced ability to kill glioblastomas in brain cancer. Glioblastoma is a form of brain cancer in which the effected cells are the glial cells that provide protection and support for the brainΓÇÖs neurons. The unique characteristic of EGF4KDEL to target glioblastoma cells is favorable because glioblastomas are characteristically unrelated to other types of carcinomas.BENEFITS OF TARGETING DRUG RESISTANT CARCINOMA CELLS WITH IMMUNOTOXINSΓÇó Immunotoxins have the ability to kill drug resistant carcinomas by an alternative mechanismΓÇó Immunotoxins take advantage of cytokine receptors present on the carcinoma cell surfaceΓÇó Higher specificity of immunotoxins can be achieved by targeting multiple receptorsΓÇó Immunotoxins can target gioblastoma cells which respond differently to conventional chemotherapy techniques

*Abstract

Immunotoxins are important treatments of drug resistant carcinomas, cancerous tumors, and glioblastomas. Immunotoxins are able to target and kill tumor cells which are not responsive to chemotherapy treatments. By tuning immunotoxins to recognize certain cytokine receptors expressed on the surface of carcinoma cells, the effectiveness of these treatments can be increased greatly and specific cancer types can be targeted.

*Principal Investigation

Name: Daniel Vallera, Professor

Department: Therapeutic Radiology

附加資料

Inventor: VALLERA, Daniel, A.
Priority Number: WO2009029601A3
IPC Current: C07K0014705 | A61K003817 | A61P003500 | C07K001900 | C12N001562
Assignee Applicant: Regents of the University of Minnesota
Title: RECEPTOR-TARGETING REAGENTS | RÉACTIFS DE CIBLAGE DE RÉCEPTEURS
Usefulness: RECEPTOR-TARGETING REAGENTS | RÉACTIFS DE CIBLAGE DE RÉCEPTEURS
Summary: The receptor-targeting reagent, composition, and methods are useful for killing a cell; treating a cancer in a subject; decreasing a toxic side-effect of an immunotoxic therapy in a subject; and selecting a therapeutic agent for a mammal with cancer. Cancer is selected from lung cancer, breast cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer, liver cancer, bone cancer, hematological cancer, neural tissue cancer, melanoma, thyroid cancer, ovarian cancer, testicular cancer, prostate cancer, cervical cancer, vaginal cancer, or bladder cancer. Preferably, the cancer is a glioblastoma (all claimed).
Novelty: New receptor-targeting reagent comprises an epidermal growth factor receptor-binding agent, and an interleukin-13 or interleukin-4 receptor-binding agent, useful for treating cancer, e.g. lung cancer, breast cancer, or colon cancer

主要類別

診斷/治療

細分類別

癌症/腫瘤

國家/地區

美國